Tasquinimod for myelofibrosis after JAK inhibitor failure
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug called tasquinimod, either alone or combined with ruxolitinib, for people with myelofibrosis. It's for patients who haven't gotten enough help from standard treatments or who can't take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of myelofibrosis that needs treatment (primary, or after polycythemia vera or essential thrombocythemia).
- Your disease must be at an intermediate or high risk level, or you have a significantly enlarged spleen causing symptoms.
- You have either tried a JAK inhibitor and it didn't work or you can't take it, OR you are currently on ruxolitinib and your spleen is still large or you have symptoms.
- You must be able to swallow pills and be at least 18 years old.
- Your blood counts must meet certain minimums (like white blood cells, kidney and liver function).
- You cannot have serious heart problems or active infections like hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This study tests an experimental drug called revumenib, either alone or combined with a JAK inhibitor, for people with myelofibrosis that is still active despite standard treatment. The goal is to see if revumenib can better control symptoms, reduce spleen size, or improve blood counts.
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Hear when a new Primary Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.